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ABSTRACT
Mobilization of stem cells with pegylated granulocyte colony-stimulating factor (peg-G-CSF) modulates donor
T- and natural killer T-cell (NKT-cell) functions, thus separating graft-versus-host from graft-versus-
leukemia disease in animal models. We report a phase I/II study that analyzed the feasibility of mobilizing stem
cells from normal donors with peg-G-CSF and the ability of these cells to restore hematopoiesis in allogeneic
transplant recipients after myeloablative conditioning. Administration of 6 mg of peg-G-CSF resulted in
suboptimal stem cell mobilization, with a peak peripheral blood CD34 count of 29  5/L. Apheresis 4 days
after peg-G-CSF yielded 2.7  .4  106 CD34 cells/kg recipient weight, and all donors required a second
collection on day 5 to yield a total of 4.2  .5  106 CD34 cells/kg recipient weight. After escalation of the
dose to 12 mg, the peak CD34 count was 99  11/L and 12 of 13 donors collected sufficient stem cells for
transplantation in a single apheresis (8.9  1.4  106 CD34 cells/kg recipient weight). Late transient
increases in serum hepatic transaminases were noted, but other side effects (predominantly bone pain) were
otherwise similar to those seen in donors mobilized with standard G-CSF. Median neutrophil and platelet
engraftments occurred on days 18 and 14, respectively, after transplantation and were identical to those seen
with in recipients of grafts mobilized with standard G-CSF. With a median follow-up of 357 days, the incidence
of grade II-IV acute graft-versus-host disease was 50% and there have been no relapses to date. Mobilization
of stem cells with peg-G-CSF in normal donors is feasible and 12 mg results in mobilization characteristics
similar to those of standard G-CSF.
© 2006 American Society for Blood and Marrow Transplantation
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mNTRODUCTION
Transplantation of peripheral blood stem cells mo-
ilized by granulocyte colony-stimulating factor (G-
SF) has become standard practice in allogeneic trans-
lantation. Despite the transfer of large numbers of
onor T cells, the incidence of acute graft-versus-host
isease (GVHD) is not increased, which is postulated to
e the result of immunomodulation by G-CSF [1,2].tRH is a Wellcome Trust Senior Overseas Research Fellow.
B&MTmmunomodulation by G-CSF is complex and involves
-helper type 2 differentiation [3,4] and the induction of
egulatory T and antigen-presenting cells [5-7]. We re-
ently reported that mobilization with G-CSF protects
gainst experimental GVHD in a dose-dependent fash-
on and that this effect is maximal after administration of
egylated G-CSF (peg-G-CSF) [8]. In addition, peg-G-
SF activates donor natural killer T (NKT) cells and
ncreases graft-versus-leukemia effects in experimental
odels [9]. We therefore initiated a phase I/II clinicalrial to examine transplantation of peripheral blood
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6rafts mobilized by peg-G-CSF and report on our initial
xperience in normal donors.
ETHODS
atient Accrual
All recipients (and donors) receiving their ﬁrst
llogeneic stem cell transplants from an HLA-
atched sibling after myeloablative conditioning and
yclosporine/methotrexate GVHD prophylaxis were
ligible. Donors and recipients were required to fulﬁll
tandard criteria for minimum organ function and
egative viral serology. Enrollment commenced in
ebruary 2004. Protocols were approved by the insti-
utional ethics committees and donors and recipients
rovided written informed consent. A cohort of 19
onors receiving stem cell mobilization with standard
-CSF over the period are included for comparison.
hese donor-recipient pairs did not fulﬁll the peg-G-
SF entry criteria, usually on the basis of condition-
ng regimen.
tem Cell Collections
All donors received a single dose of peg-G-CSF
Neulasta, Amgen, Thousand Oaks, Calif) at 6 mg
ubcutaneously on day 0. Full blood counts, biochem-
stry, and CD34 counts were monitored days 2-5 and
2 after peg-G-CSF administration. Donors were har-
ested on day 4 by standard apheresis (Cobe Labora-
ories, Lakewood, Calif; 3 blood volumes). Target
tem cell yield was 4-8  106 CD34 cells/kg recip-
ent ideal body weight. If 4  106 CD34 cells/kg
ecipient ideal weight was not achieved in a single
ollection, a second collection was performed on day 5
nd products were combined and infused on day 0.
ata are based on recipient ideal body weight. Donors
ompleted side effect questionnaires until full recov-
ry and side effects were graded from 0 (normal) to 10
severe). The cohort of donors receiving stem cell
obilization with standard G-CSF received 10
g · kg1 · d1. Dose escalation to 12 mg was planned
f stem cell mobilization with 6 mg of peg-G-CSF was
nferior to that seen with standard G-CSF.
ransplantation Protocols
Transplant recipients were conditioned with cy-
lophosphamide (60 mg/kg on days 5 and 4) and
otal body irradiation (TBI) (2 Gy twice daily on days
3 to 1) or with ﬂudarabine (30 mg/kg on days 6
o 2) and melphalan (120 mg/kg on day 1). All
ecipients received cyclosporine (5 mg/kg on days 1
o 1 and then 3 mg/kg [ideal body weight]) adjusted
o therapeutic institutional levels. Methotrexate was
dministered on day1 (15 mg/m2) and days3,6,
nd 11 (10 mg/m2). G-CSF after transplantation
as limited to recipients with delayed neutrophil re- g
04overy (.5  109/L) on day 21. Supportive care
as as previously described [10].
valuation and Definitions
Stem cell products were analyzed as previously
escribed [11]. Neutrophil engraftment was deﬁned as
ccurring on the ﬁrst of 3 days with a neutrophil count
.5  109/L after the post-transplant nadir. Organ
oxicities were graded using National Cancer Institute
riteria. Platelet engraftment was deﬁned as occurring
n the ﬁrst of 5 consecutive days with a platelet count
20  109/L without platelet transfusions. Acute
VHD was graded by Seattle criteria [12].
ESULTS AND DISCUSSION
onor Characteristics
Donor characteristics are listed in Table 1 and side
ffects in those receiving 6 and 12 mg of peg-G-CSF
ere similar (predominantly bone pain). White blood
ell count peaked 2-3 days after the 6-mg dose of
eg-G-CSF and was signiﬁcantly lower than in donors
eceiving 12 mg, which peaked later. Platelet nadirs
ere lowest in donors receiving 12 mg of peg-G-CSF
ut remained at acceptable levels (Table 1 and Fig-
re 1).
Liver function changes were characterized by in-
reases in serum alkaline phosphatase, which peaked
n days 4-5 and correlated with the dose of peg-G-
SF. National Cancer Institute grade 2 toxicity was
een in 1 of 5 donors receiving the 6-mg dose and 7 of
3 receiving the 12-mg dose. Increases in alkaline
hosphatase and lactate dehydrogenase were not sig-
iﬁcantly different between the 6- and 12-mg cohorts
Table 1). However, increases in alanine aminotrans-
erase (ALT) were seen after stem cell collection, ie,
-12 days after peg-G-CSF administration. Of the 5
onors receiving the 6-mg dose, 2 had National Can-
er Institute grade 1 toxicity and 1 had grade 2. Of the
3 donors receiving the 12-mg dose, 7 had grade 1
oxicity, 1 had grade 2, and 1 had grade 3. The donor
ith grade 3 toxicity also developed palpable spleno-
egaly, which was conﬁrmed on ultrasound and was
ransient. Increased ALT, which occurred in 66% of
onors, was also transient and returned to normal
evels by a median of 24 days (range, 5-37) after
eg-G-CSF administration. There were also associ-
ted but less marked increases in aspartate amino-
ransferase in 25% of donors (median, 32; range, 21-
43; normal, 40) but no increases in serum bilirubin
ere seen. The mean increase in ALT in donors
eceiving 12 mg of peg-G-CSF was higher than that in
hose receiving 6 mg (103  38 versus 52  16 U/L;
ormal, 45 U/L). Although 1 donor receiving stan-
ard G-CSF over the same time period developed a
rade 2 increase in ALT, this group was not routinely
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Peg-G-CSF Mobilized Stem Cells for Allogeneic SCT
Bonitored after day 4, so late increases in ALT would
ot have been detected. We therefore monitored liver
unction on days 6 to 9 after standard G-CSF admin-
stration in the next 10 normal donors and observed
rade 1 increases in ALT in 50% of individuals (me-
ian peak ALT, 48 U/L; range, 14-70), suggesting this
ffect is not peculiar to peg-G-CSF. Nevertheless,
rade 2 and 3 increases in ALT after administration of
eg-G-CSF have prompted us to exclude donors with
bnormal liver function and restrict alcohol and parac-
tamol consumption during stem cell mobilization and
or the week thereafter. Grade 1 increases in ALT were
een only in the subsequent cohort of 4 recipients.
tem Cell Products
After mobilization with 6 mg of peg-G-CSF, in-
reases in CD34 counts were modest, peaking 3 days
fter administration (mean  SE, 29  5/L). Col-
ection of CD34 stem cells on day 4 was suboptimal
2.7  .4  106/kg recipient weight) and all patients
equired a second collection on day 5 (yielding 1.5 
3  106/kg recipient weight), which, when combined
ith the day 4 collection, yielded a total of 4.2  .5 
06 CD34 cells/kg recipient weight (Figure 1 and
able 1). Of the donors mobilized with standard G-
able 1. Donor Characteristics, Side Effects, and Graft Composition*
Units (Normal Range)
peg-G-CSF (6 m
(n  5)
onor characteristics
Age, y 40 (28-50)
Weight, kg 76 (63-80)
Male:female 3:2
G-CSF total dose, g/kg 79 (75-95)
ide effects
Maximal lower back pain (0-10) 7 (4-8)
Days of lower back pain 5 (3-9)
Maximal headache (0-10) 5 (6-8)
Days of headache 5 (0-10)
Maximal myalgia (0-10) 6 (0-7)
Days of myalgia 4 (0-11)
Maximal fatigue (0-10) 6 (2-10)
Days of fatigue 10 (4-18)
Peak WBC, 109/L (<10) 33 (28-40)
Platelet nadir, 109/L (150-450) 144 (124-150)
Peak ALP, U/L (40-110) 208 (118-280)
Peak LDH, U/L (110-250) 279 (199-470)
Peak ALT, U/L (<45) 43 (20-113)
ellular content of infused grafts
Total nucleated cells/kg (108) 14.4  1.7
CD34/kg (106) 4.2  0.5
CD4/kg (106) 254  36
CD8/kg (106) 120  19
WBC indicates white blood cell count; ALP, alkaline phosphatase;
(range) or mean  SE and compared by Mann Whitney U test
P  0.05.
P  0.01, peg-G-CSF 12 mg versus 6 mg.
P  0.05, G-CSF versus peg-G-CSF 6 mg.
P  0.05, G-CSF versus peg-G-CSF 6 and 12 mg.SF, 32% collected 4  106/kg recipient weight in s
B&MTsingle collection on day 4. Because mobilization of
tem cells with the 6-mg dose of peg-G-CSF was
igniﬁcantly inferior to that seen with standard G-
SF (Figure 1), the dose was increased to 12 mg. At
his dose, stem cell mobilization was robust, with stem
ell counts peaking on day 4 at 99  11 CD34
ells/L of peripheral blood (mean  SE). Twelve of
3 donors collected adequate numbers of CD34 cells
or transplantation (4  106/kg recipient weight) in
single apheresis on day 4 (8.9  1.4  106/kg
ecipient weight) and 7 of 13 collections were only
artly infused to maintain the numbers of CD34
ells transplanted at 8  106/kg recipient weight.
he cellular content of infused grafts from donors
obilized with 12 mg of peg-G-CSF was similar to
hat mobilized by standard G-CSF or 6 mg of peg-G-
SF (Table 1). Because of the superior mobilization
ith peg-G-CSF at the 12-mg dose compared with
tandard G-CSF, the predicted rate of failure to mo-
ilize would be expected to be similar to or lower than
hat seen with standard G-CSF.
ecipient Characteristics, Engraftment, and
ransplantation Outcome
Characteristics of transplant recipients with as-
peg-G-CSF (12 mg) G-CSF (10 g/kg)
(n  13) (n  19)
42 (23-62) 48 (14-65)
80 (60-115) 91 (53-126)
9:4 12:7
150 (104-200) 40
5 (0-9) N/A
5 (0-16) N/A
5 (0-10) N/A
3 (0-9) N/A
3 (0-8) N/A
4 (0-10) N/A
5 (0-9) N/A
7 (0-20) N/A
48 (37-70)‡ 44 (26-83)§
109 (70-178)† 243 (114-349)
295 (190-434) 250 (141-682)
419 (322-809) 414 (235-611)
71 (15-541) 26 (11-186)
11.8  1.3 9.4  0.7§
6.3  0.5† 5.8  0.7
168  24 161  12
73  15† 83  7
actate dehydrogenase; N/A, not assessed. Data expressed as mediang)
LDH, l
.essable acute GVHD data (transplanted 100 days
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6reviously) are presented in Table 2. The mean num-
er of CD34 cells actually transplanted from peg-G-
SF mobilized donors was 5.7  .4  106/kg recipi-
nt weight and the 6- and 12-mg cohorts are
onsidered together for engraftment purposes because
he ﬁnal number of CD34 cells infused to donors was
dequate in both groups. Recipients transplanted with
tem cell grafts mobilized with peg-G-CSF achieved
eutrophil and platelet engraftment at a median of 18
nd 14 days, respectively, after transplantation (Table
), with stable engraftment maintained at a median
ollow-up of 357 days (range, 188-632) in surviving
ecipients. The median of neutrophil and platelet en-
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Stem cell mobilization
 D
igure 1. Analysis of stem cell mobilization, collection, and engraft
A) White blood cell and (B) CD34 counts were determined by aut
ircles indicate 6 mg of peg-G-CSF (n  5), and open circles repre
and CD34 counts were determined by ﬂow cytometry in the (C)
ashed lines represent the lower threshold in stem cell grafts requir
cceptable CD34 number in stem cell products for transplantation
g · kg1 · d1 of standard G-CSF on days 0-3 (n  19). E, Neut
y peg-G-CSF (n  14). Data were compared by Mann Whitneyraftment for 9 recipients receiving allogeneic stem G
06ell grafts mobilized by standard G-CSF after cyclo-
hosphamide/total body irradiation conditioning over
he same period was 18 days (range, 12-24) and 13
ays (range, 7-25), respectively. Further, the median
umber of red blood cell and platelet transfusions for
hese recipients was similar at 8 (range, 2-27) and 9
range, 2-15), respectively.
Seven recipients (50%) developed at least grade II
cute GVHD (Table 2). Four recipients developed
evere (grade III/IV) acute GVHD (29%) involving
he gastrointestinal tract that was refractory to steroid
herapy in 3 cases, requiring therapy with antithymo-
yte globulin. Three of these recipients died from
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Bhe incidence of grade II-IV acute GVHD and grade
II/IV acute GVHD at The Royal Brisbane unit was
reviously reported as 54% and 43%, respectively, in
his setting [10]. No recipients have developed hema-
ologic relapse to date.
Mobilization of stem cells with peg-G-CSF in nor-
able 2. Recipient Characteristics and Outcome After
ransplantation*
Recipients of peg-
G-CSF Grafts
(n  14)
ecipient characteristics
Age, median (range) 46 (21-57)
Male:female 10:4
Disease
AML 9
ALL 2
CML 2
CLL 1
Conditioning
Cy/TBI 13
Flu/Mel 1
Disease status
Early† 9
Advanced 5
ngraftment
Neutrophil recovery, median (range)‡ 18 (11-22)
Platelet recovery, median (range)‡ 14 (8-27)
RBC transfusions, median (range)§ 5 (0-33)
Platelet transfusions, median (range) 4 (1-19)
cute GVHD
Grade, n (%)
0-I 7 (50%)
II 3 (21%)
III/IV 4 (29%)
Grade II-IV organ involvement, n (%)
Skin 7 (50%)
Gut 5 (36%)
Liver 4 (29%)
Overall survival, n (%) 11 (79%)
Hematologic relapse 0 (0%)
Median days of follow-up (range)# 357 (188-632)
AML indicates acute myoblastic leukemia; ALL, acute lympho-
blastic leukemia; CML, chronic myoblastic leukemia; CLL,
chronic lymphoblastic leukemia; Cy/TBI, cyclosporine/total
body irradiation; Flu/Mel, ﬂudarabine/melphalan; RBC, red
blood cell.
First chronic phase.
As deﬁned in Methods.
Number of units.
Four units of multidonor platelets.
Follow-up is for surviving patients.al donors is feasible. Further data are required to more
B&MTlosely analyze the effect of peg-G-CSF on donor liver
unction and the ability of these stem cell grafts to induce
VHD and graft-versus-leukemia effects.
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